12 June 2018 - - Vienna, Virginia-based drug and vaccine developer CEL-SCI Corp. (NYSE American: CVM) has received two new US patents for the LEAPS platform technology from the US Patent and Trademark Office (USPTO), the company said.
CEL-SCI's patented inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
The LEAPS platform technology, currently being developed as a therapeutic vaccine for rheumatoid arthritis under a USD 1.5m grant from the US National Institutes of Health, is a T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens.
LEAPS compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This platform technology has been shown in several animal models to preferentially direct the immune response to a cellular, humoral, or mixed pathway and has been shown to involve upregulation of T-regulatory cells in some animal models.
It has the potential to be utilised in diseases for which antigenic epitope sequences have already been identified, such as: a number of infectious diseases, some cancers, autoimmune diseases, allergic asthma and allergy, and select central nervous system diseases.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.